NeuroVive share upgraded on OTC market in US
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company’s share has been upgraded from trading on the OTC Grey Market to OTC Pink in the US. The upgrade implies increased accessibility and transparency, and improves the potential to attract interest from US investors. This is in line with the company’s strategy to increase its presence in the US, the world’s largest pharmaceuticals market.Since March 2014, US investors have been able to trade electronically in the NeuroVive share in USD on the OTC Grey Market without requiring a Swedish broker